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EFFECT OF LIPOPOLYSACCHARIDE ON C3 AND C5 PRODUCTION BY HUMAN 
LUNG CELLS 
BARBARA L. ROTHMAN,, MARTHA MERROW,+ ALAN DESPINS,* THOMAS KENNEDY,' AND 
DONALD L. KREUTZER2' 
From the  'Department of Pathology  and  'Department of Pediatrics,  Universlty of Connecticut  Health  Center, 
Farmington, CT 06032 
Although studies to  date have demonstrated the 
ability of the monocyte/macrophage to produce C 
components in vitro, very few studies on C produc- 
tion by nonhepatic tissue cells have been reported. 
Recently, using 35S-methionine incorporation and 
immunoprecipitation techniques our laboratory has 
demonstrated the ability of tissue cells, i.e., the 
human lung type I1 pneumocyte  (A549) and human 
lung fibroblast (WI-38), to synthesize and  secrete a 
variety of early and terminal complement  compo- 
nents, as well as several regulatory proteins in vitro, 
i.e., Clr, Cls, C4, C3, C5, C6. C7, C8. C9, factor B, 
factor H, factor I, and Cls inactivator. In our studies, 
we extended these observations by demonstrating 
the capability of  LPS to modulate C3 production by 
A549 pneumocytes.  Specifically,  using  a sensitive 
ELISA we demonstrated that A549 pneumocytes 
exposed to LPS induced an 80 to 180% increase in 
C3 levels  when  compared to untreated A549 cells. 
Interestingly, LPS had no effect  on C5 production 
or total protein synthesis by  A549 pneumocytes. In 
the case of the WI-38 fibroblast, LPS had no effect 
on 1) C3 production, 2) C5 production, or 3) total 
protein synthesis in vitro. These studies demon- 
strate  that agents  such as LPS have the potential to 
selectively regulate C production (i.e.,  C3) in individ- 
ual lung cells in vitro, and suggests that in vivo  LPS 
may alter  the local tissue reservoir of C components 
during infection and lung injury, thus impacting on 
pulmonary  inflammation and host defense. 
Although previous  studies  have focused on various as- 
pects of C component production by inflammatory cells 
(i.e., monocyte/macrophage), very little is known  about 
the capability of normal  or injured tissue cells to produce 
C  components in vivo or  in vitro (1). Specifically, studies 
on tissue cell production of C have demonstrated: 1) 
epithelial cells from the  gastrointestinal  and genitouri- 
nary  tracts produce C1 (2);  2)  fibroblasts  can  synthesize 
C1, C3, factor B and factor H (3-7); and 3) lung macro- 
phages produce C2, C4, C3. and factor B (8-10). Our 
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laboratory has studied complement production (i.e.,  syn- 
thesis,  secretion, and metabolism) by prototypes of tissue 
cells, Le., the  lung type I1 pneumocyte (A549) and  lung 
fibroblast (WI-38) (1  1 -13). Using 35S-methionine incor- 
poration and immunoprecipitation of specific C compo- 
nents we demonstrated the capability of these lung cells 
to  synthesize and  secrete  numerous C components and 
regulatory proteins  including Clr, Cls, C4, C3, C5, C6, C7, 
C8, C9, factor B, factor H, factor I, and Cls inactivator  in 
vitro (1 1). Additionally, we have further characterized the 
physical and antigenic nature of the C3 and C5 produced 
by these cells, as well as the kinetics of C3 and C5 
production (1 1). These  studies revealed four  important 
findings: 1) in vitro, the type I1 pneumocyte and lung 
fibroblast can synthesize and secrete  a wide variety of 
early and terminal C components: 2) these lung cells 
synthesize and secrete a number of C components (e.g.. 
C6, C7, C8, or C9) which are not thought  to  be produced 
by the monocyte/macrophage; 3) type I1 pneumocytes 
produce significantly  greater amounts of C3 (20-fold), as 
quantitated by an ELISA, than  that reported for the mon- 
ocyte (1 4); and 4) using  35S-methionine  incorporation a d 
immunoprecipitation techniques, the C3 and C5 pro- 
duced by the type I1 pneumocytes is antigenically and 
physically (i.e.,  m.w.)  identical  to  serum C3 and C5 (1  1). 
Recent studies by Strunk  et al. (1 5) using  primary cul- 
tures of type I1 pneumocytes  have confirmed our obser- 
vations  with the A549 pneumocyte. Le., human type I1 
cells synthesize C2, C4, C3, C5, and factor B. These data 
not only demonstrate  the in vitro ability of tissue cells to 
produce C  but clearly underscore the possible impact of 
the C components produced by lung cells to the local C 
reservoir within  lung  tissue. Additionally, these  studies 
suggest that compartmentalization of local C production 
by individual lung cell and inflammatory cell populations 
may occur. Le., different  C  components being produced 
by different cell types. Thus, local tissue C levels likely 
represent  the  result of the contribution of not only hu- 
moral C  components,  but  also  tissue and inflammatory 
cell-derived C components. 
Clearly, alterations in the  balance of tissue C levels 
could result from stimulation and/or suppression of C 
component  synthesis,  ecretion  and/or metabolism 
within individual cell populations. Thus,  agents or fac- 
tors that  enhance or suppress production of C compo- 
nents by recruited or tissue cells would likely have a 
significant  impact on tissue  C levels and  the resulting 
tissue  inflammation and host  defense. Endotoxin (LPS) 
has been demonstrated  to  induce pulmonary inflamma- 
tion.  activate the C  system,  and  alter C synthesis in the 
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monocyte/macrophage (16). In our studies we examined 
the  effects of LPS on C production by type I1 pneumocytes 
and lung fibroblasts. These  studies demonstrate that type 
I1 pneumocytes exposed to LPS produced 80 to 180% 
greater C 3  levels in comparison to untreated cells. Inter- 
estingly, LPS had no effect  on C 5  production or protein 
synthesis by type I1 pneumocytes. Additionally,  we dem- 
onstrated that LPS could not regulate C 3  or C5 production 
by human lung fibroblasts. Thus,  these studies not only 
demonstrate the capability of LPS to selectively regulate 
complement production (i.e., C 3 )  by  type I1 pneumocytes, 
but that this regulation may  be unique to the type I1 cell, 
because it does not occur in the lung fibroblast. These 
observations suggest that during  pulmonary disease as- 
sociated with gram-negative bacterial infection, resident 
lung cells  [such as type I1 pneumocytes) may contribute 
to  pulmonary host  defense  and inflammation by  directly 
altering tissue  levels of important C components such as 
c3. 
MATERIALS AND METHODS 
A549  and  WI-38 cell cultures. Passage  76  human lung type I1 
pneumocyte cell line (A549: ATCC  CCL 185),  and passage 13  human 
lung  fibroblast cell line (WI-38: ATCC  CCL 75) were purchased from 
American Type Culture Collection (Rockville, MD). The A549 cell 
line  was  maintained  in  F12  Ham's medium (Kansas City Biological, 
Kansas City, MO) and  the WI-38 cell line  was  maintained  in Eagle's 
MEM (Kansas City Biological). Both types of media were supple- 
mented with 15% FBS3 (Sterile Systems. Inc., Logan, UT). 20 pgjml 
gentamicin. 0.5 pgjml amphotericin B, 0.1 mM nonessential  amino 
acids, 4 mM glutamine,  and 1 m1/100 ml medium of MEM vitamins 
(1OOx) (GIBCO. Grand Island, NY). Routine subcultures for A549 
pneumocytes (passage 76 to  94)  and WI-38 fibroblasts  (passage 13  
to  22) were done at  1:3  split  ratios by incubation  with  0.05%  trypsin 
0.02%  ethylene  diaminetetraacetic acid in calcium-magnesium free 
HBSS  (GIBCO) for 5 to 9 min a t  37°C.  Cell cultures were incubated 
a t  37°C in a humidified incubator  with 5% COz in  air. 
Cell culture  conditions for  sample collection. The  A549  and WI- 
38 cell lines were grown in 75  cm2  tissue  culture  flasks  (Falcon, 
Oxnard, CA) in the appropriate complete media described above. 
Confluent WI-38 fibroblast  cultures  (1 X lo' cells/flask) or confluent 
A549 pneumocyte cultures (1 x lo7 cells/flask) were used for all 
studies. C  production experiments were  begun by rinsing  the con- 
fluent cell cultures  three  times with 10 ml sterile  saline, followed  by 
the addition of 10 ml of serum  free or 15% FBS supplemented media 
with or without LPS. These  flasks were then  incubated  at 37°C in a 
humidified incubator  with 5% C02  in  air for 11  days. On day 1,3, 5, 
7 and 9. a 5-ml sample of medium from each cell culture  flask  was 
collected and replaced with 5 ml of the  appropriate  fresh medium. 
On the  last  day of culture (i.e.. day 1 l),  the total cell culture  super- 
natant  was  harvested. All culture  supernatant  samples were centri- 
fuged at  400 Xg for  10  min  to remove cellular  debri then divided into 
1-ml aliquots  and stored at  -70°C. 
Cell culture  with LPS. Experiments  examining  the  effects of LPS 
on  C  production by lung cells  were  performed by adding  100 pgjml 
TCA extracted LPS from Escherichia serotype no, 055:B5 (LPS) 
(Sigma Chemical Co., St. Louis, MO). 
Antiserum. The IgG fraction of goat anti-human C3 was pur- 
chased from Cappel Laboratories  (Malvern. PA). Rabbit anti-human 
C5 antibody  was prepared by immunizing rabbits  subcutaneously 
with 250 pg purified human C5 (Calbiochem Biochemicals, San 
Diego.  CA) in CFA (Difco Laboratories,  Detroit, MI) (17).  Serum  was 
isolated from rabbit blood and tested  for anti-human C5 antibody 
titer by double immunodiffusion analysis. Both normal human 
serum  and C5  deficient human  serum  (18) were  used to validate the 
specificity of the  anti-human C5 antiserum. Rabbit anti-human C5 
IgG was purified using Protein A Sepharose 4B (Pharmacia Fine 
trophoresis  against purified C5, normal  human  serum, or C5-defi- 
Chemicals.  Piscataway. NJ) .  and  assayed  for purity by immunoelec- 
cient  human  serum. Alkaline phosphatase conjugated to  antiserum 
or Ag was  prepared by the method of Voller et  al.  (19).  The enzyme 
preparation used 
act.  1000 U/mg. 
was alkaline phosphatase, Sigma VII-s oi' SP. 
3Abbreviations used in this paper: FBS. fetal bovine serum: LDH. 
lactate dehydrogenase: S I ,  stimulation index. 
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ELISA for  human  C3 Ag.  The  immunoassay  to  quantitate  human 
C3 Ag was performed in 96-well flat-bottom  microtiter  plates (Flow 
Laboratories, McLean, VA) using a competitive ELISA technique  (1  1, 
20,  21).  The lower limit of detection  for this ELISA was 50 ng C3/ 
ml. Because the A549 pneumocyte and WI-38 fibroblast  cells were 
grown in media containing  15% FBS, the cross-reactivity of the FBS 
was  tested in this ELISA and  was found to  have no  detectable  cross- 
reactivity. 
ELISA for  human C5 Ag. The  immunoassay  to  quantitate C5 Ag 
was performed in 96-well  flat-bottom  microtiter  plates (Flow Labo- 
ratories, McLean, VA) using a competitive ELISA procedure (1  1, 20). 
The lower limit of detection for  this ELISA was 50 ng C5/ml. Because 
the A549 pneumocyte and WI-38 fibroblast cells were grown in 
media containing  15% FBS, the cross-reactivity of the FBS in  this 
ELISA was tested and  no significant  cross-reactivity was  found. 
Functional assay for  human  C5. A hemolytic assay  to  quantitate 
functional C5 (CsHso) was performed using antibody-coated sheep E 
in veronal-buffered saline with 0.1 % gelatin, 0.15 mM Ca++,  and 1.O 
mM Mg". Generally, 250 pl of purified C5 (Calbiochem Biochemicals, 
San Diego.  CA) or test  sample  was added to  250 pl  of a 4.0% solution 
of C5-deficient serum  (18). Next, 125 pl of antibody-coated sheep E 
(3.33 x lo7 cells/ml) was added to  the mixture, followed by a 60-min 
incubation at  37°C. After incubation, 1.0 ml isotonic saline was 
added and the samples were centrifuged at 450 x g  for 6 min. 
Hemolysis was determined by evaluation of the OD at  41 2 nm of the 
dilution at  which 50% RBC lysis  occurred in relation to the highly 
resulting  supernatants. Results  were  calculated by comparing the 
purified C5  which was used as  the  standard in each  assay.  The  50% 
lysis point for this  assay  was approximately 1 to 5 ng C5/ml, and  no 
cross reactivity  between human C5 and FBS was detected using  this 
functional  assay. 
Protein synthesis  by  A549  pneumocytes. To incorporate radio- 
active amino  acids  into  proteins  synthesized by A549 pneumocytes. 
the cells were grown to confluence  in 48-well plates  and  maintained 
in  serum-free, methionine-free F12 Ham's medium for  16 h  in the 
presence of 50 pCi/ml ~-[~~S]methionine  (1  120 pCi/mmol. New Eng- 
land Nuclear, Boston, MA) and LPS. At selected times in culture, 
after exposure to LPS, cell supernatants were collected, centrifuged 
400 x g  for 10  min, aliquoted. and stored at  -70°C. These  culture 
TCA precipitation, i.e.,  equal volumes of [35S]methionine labeled cell 
supernatants were used  for analysis of total  protein synthesis  using 
culture supernatant and 10% TCA. and 1% albumin as carrier 
protein,  were incubated at  4°C for 30 min and  then centrifuged at  
400 Xg for  20 min to precipitate  [3sS]methionine  incorporated pro- 
teins. 
Protein assay. A549  pneumocyte and WI-38 serum  free  culture 
supernatants were analyzed for total  protein content  using a micro- 
described by Bradford (22). 
protein assay with a sensitivity range of 1 to 10 rg protein/O. 1 ml as 
Cell uiability. Cell viability was examined by uptake of vital dye 
Erythrocin  B (J. T. Baker Chemical Co.. Phillipsburg, N J )  or Trypan 
Blue (GIBCO) and visualized by light microscopy. In addition, LDH 
levels in cell culture  supernatants were also used as a n  indicator of 
cell death or cell integrity (23). All LDH data  was expressed as  the 
percent of total LDH. where total LDH equaled the LDH released into 
the  supernatant  from 1 X lo7 A549 pneumocytes after exposure to 
Triton  X-100. The percent LDH was calculated using  the following 
equation: 
% LDH = 
LDH content  in experimental culture  supernatant 
Total LDH 
x 100 
Data analysis. Quantitation of absolute Complement component 
levels in individual cell culture  supernatants were determined by 
direct  comparison to  the  standard  curves of known C3 and C5 Ag in 
the  appropriate ELISA system  and  the  final  data were  expressed as  
ngjml. 
Quantitation of the total accumulation Complement component 
levels in each culture supernatant were determined by using the 
equation below and  the  final  data were expressed as ngjml: 
Y, = X" + XI2J-r) 
j = l  
n.  days in culture, i.e. day 1,3,5.   7,  9 or 11: X,. absolute component 
protein  detected in a culture  supernatant  harvested on  day n; Y,. 
total accumulated complement  protein produced by cells  in culture 
from day 0 to day  n. 
All data  are expressed as  the  mean -C SEM. and  statistical signif- 
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icance of the data was determined using the unpaired Student's t- 
test (24). SI was calculated using the following general equation: 
S I  = 
experimental value 
control value 
SI.. SI for  radioactive amino acid Incorporation: SIcs. S I  for antigenic 
C3: SIc5, S I  for antigenic C5; and SIcsr. SI for functional C5. 
Percent functional C5 levels were  determined using  the following 
equation: 
total accumulated functional C5 
% functional C5 = (ng/ml) on day n 
total accumulated antigenic C5 x 100 
(ng/ml) on day n 
RESULTS 
Efect of FBS on C component  production  by A 5 4 9  
pneurnocytes. During the course of our  initial investiga- 
tions on C component production by type I1 pneumocytes 
we noted that different  lots of FBS influenced the abso- 
lute  amount of the  third (C3) and  fifth (C5) C  components 
produced by A549 pneumocytes  in vitro. To control for 
this effect in  our  studies, we cultured A549 pneumocytes 
in two different lots of FBS for 11 days and analyzed 
culture  supernatants obtained on days  1, 3, 5, 7, 9, and 
1  1 for antigenic C3  and C5 levels by  ELISA. These  studies 
demonstrated that lot no. 2 stimulated a significantly 
greater  rate of antigenic C 3  production when compared 
to the stimulatory  effect of lot no. 1, i.e., 335 vs 135  ng 
C3/m1/24 h. Additionally, baseline  C3 production in 
serum  free medium was  similar  in  all the  studies, i.e., 
cultures of A549 pneumocytes  maintained  in  serum-free 
medium produced antigenic  C3 at similar  rates 62  ng C3/ 
m1/24 h (lot no. 1  studies)  vs 70 ng C3/m1/24 h (lot no. 2 
studies).  Further  investigations  with  a  third lot of FBS 
revealed similar  effects on C3 production by A549 cells 
as described for lot no. 2  (data not shown).  Similar data 
were obtained  when these  same A549 pneumocyte cul- 
ture  supernatants were analyzed  for C5 production. Spe- 
cifically, lot no. 2  stimulated  antigenic C5 production at 
a rate of 320  ng C5/m1/24 h  in  comparison to the  rate of 
245 ng C5/m1/24 h  determined for lot no. 1. Once again 
control cultures of A549 pneumocytes  cultured  in  serum- 
free medium produced antigenic C5 at similar rates  (1  48 
ng vs 153 ng C5/m1/24 h). Interestingly,  although there 
were detectable  variations  in the absolute amount of C3 
and C5  produced by A549 pneumocytes  cultured in dif- 
ferent lots of FBS, the  absolute  amounts of C3 and C5 
produced by A549 pneumocytes  cultured  in an  individual 
lot of FBS remained  consistent from experiment  to ex- 
periment. Additionally, when  experimental  results were 
expressed as SI the modulation of C  component produc- 
tion during  exposure  to LPS was  constant, with  less than 
10% variation  under any experimental  condition, regard- 
less of the lot of FBS used (see below). Additionally, 
baseline C3 and C5 production in serum-free medium 
was  similar  in  all the  studies. 
Toxicity of LPS on A 5 4 9  pneurnocytes. Although LPS 
modulation of C production by monocyte/macrophage 
has been demonstrated  (1 6), only recently has a single 
study on the  effects of LPS on C3  or C5 production by 
tissue cells been reported (1 5). Therefore, the  effects of 
LPS on C component production by human type I1 pneu- 
mocytes in vitro was studied by culturing A549 pneu- 
mocytes in  the presence of LPS. To begin these  studies, 
we evaluated the viability of A549 pneumocytes  cultured 
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in  the presence or absence of LPS.  Morphologically, A549 
pneumocytes cultured in the presence of FBS with or 
without LPS (1 0 to 500 pg/ml) remained a tightly packed 
epithelial cell monolayer. A549 cells cultured  in the  ab- 
sence of FBS, appeared  spindle  shaped and irregular, and 
addition of LPS (1 0 to 500 pg/ml) to serum  free  cultures 
did not  alter cell  morphology (data not  shown). In addi- 
tion,  A549 pneumocytes cultured in the presence of LPS 
displayed excellent cell viability and cell integrity as de- 
termined by: l )  exclusion of vital dyes; 2) no significant 
release of total LDH during LPS exposure, e.g., the total 
LDH release from A549 pneumocytes cultured  in  serum- 
free medium alone  was 1.26 vs  3.77% total LDH release 
by A549 cells cultured  in  serum  free medium and LPS 
(100 pg/ml) on day 3. with  no additional increase above 
control levels detected on day 7; and 3) electron micro- 
scopic analysis which showed A549 pneumocytes ex- 
posed to LPS (100 pg/ml) had normal ultrastructural 
characteristics,  similar  to  untreated cells (data not 
shown). 
LPS and C 3  production by A549  pneurnocytes. To 
begin our  studies on LPS modulation of C production by 
type I1 pneumocytes  in  vitro, we initially examined the 
effects of LPS concentration on C3 production by A549 
pneumocytes. Figure 1 demonstrates that various con- 
centrations of LPS stimulated increased production of 
total accumulated antigenic C3 by A549 pneumocytes 
during  11  days  in  culture,  and that on day 3 of culture 
maximum stimulation of C3  was detected for all  concen- 
trations of LPS examined. Although there appeared  to be 
a dose-dependent increase in the stimulation of C3  by 
A549 pneumocytes in  response to various  concentrations 
of LPS, 100 pg/ml LPS was used in all the following 
studies  because  100 pg/ml  LPS was  the lowest concen- 
tration analyzed that resulted  in the most constant  stim- 
ulation response  during  11  days in culture. 
We further investigated the  effects of  LPS (100 pg/ml) 
on the kinetics of C3 production by A549 pneumocytes 
by analyzil 
5 , 7 , 9  and 
"g 
1: 
2 e 0.75, 
1 
culture supernatants obtained on day 1 ,  3, 
1 for antigenic C 3  levels. As  shown  in Figure 
T 4 10 ug/rnl 4 100 ugh1 
+- 500 ug/rnl 
+ 
0 2 4 6 8 1 0  1 2  
DAYS IN CULTURE 
Figure I .  Effects of LPS concentration on C3 production by A549 
pneumocytes.  The  closed  triangies represent the stimulation index cal- 
culated for C3 production (SIc3: mean f SEM) by A549 pneumocytes 
cultured with 10 rg  LPS/ml (n  = 4). The open  squares represent the SI,, 
for A549 pneumocytes cultured with 100 pg LPS/ml (n = 4). The closed 
squares represent the SIcs for A549 pneumocytes cultured with 500 pg 
LPS/ml (n = 31. All data are from culture supernatants obtained from cell 
cultures maintained in the presence of 15% FBS. 
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2 LPS stimulated A549 pneumocytes to produce greater 
absolute and total  accumulated  antigenic C3  levels, 
whether  the cells were cultured  in  serum-free or FBS- 
containing  culture  conditions. Analysis of data  in Figure 
2  demonstrated that during 11 days  in  culture,  the  rate 
of antigenic  C3 production was  347.2 k 54.6  ng C3/ml/ 
24 h  for A549 cells  cultured in FBS containing medium 
vs 486.3 f 85.7  ng C3/m1/24 h  for cells cultured  with 
LPS. In comparison, A549 pneumocytes  cultured  in 
serum-free medium and LPS exhibited a significant  en- 
hancement in the rate of C3 production. Specifically, 
A549 pneumocytes cultured in serum-free medium for 
11 days produced antigenic  C3 at a rate of 90.3 & 22.3 
ng C3/m1/24 h, which  increased  to 210.8 f 33.4  ng C3/ 
m1/24 h  when A549 cells  were  cultured  with LPS ( p  < 
0.02). Additionally, analysis of nine independent  experi- 
ments for the S I  for antigenic C3 production for each 
time point demonstrated that A549 pneumocytes cul- 
tured  in FBS-containing medium and LPS had  a maxi- 
mum SIc3 = 1.83 f 0.10,  whereas A549 cells cultured in 
serum-free medium plus LPS had a maximum SIc3 = 2.78 
2 0.19 (Fig. 3). 
LPS and C5 production  by A549 pneumocytes. A549 
pneumocyte culture  supernatants were also  analyzed for 
effects of LPS on antigenic C5 and functional C5 produc- 
tion. Generally, LPS had no enhancing or suppressing 
effects on antigenic C5 levels or  functional C5 activity 
detected in A549 pneumocyte  culture supernatants. 
A549 pneumocytes cultured in serum-free medium for 
11 days,  with  or  without LPS, had  almost  identical rates 
of antigenic C5 production (1  16.4 f 17.6  vs  118.9 f 19.8 
ng C5/m1/24 h),  and similar  rates of functional C5 pro- 
duction (124.3 f 7.1 vs 131.1 & 9.5 ng C5/m1/24 h). 
Similarly,  when A549 pneumocytes were cultured for 1  1 
days  in medium supplemented  with FBS, with or without 
LPS, LPS had no effect on the  rate of antigenic C 5  pro- 
duction (342.3 & 57.8  vs 314.1 f 69.2  ng C5/m1/24 h), 
or on the  rate of functional C5 production (284.8 f 58.0 
tion by A549 pneurnocytes. The open 
Figure 2. Effect of LPS on C3 produc- 
bars represent absolute antigenic C3 lev- 
els [ng/rnl] detected in culture superna- 
tants obtained from A549 pneurnocyte 
cultures maintained in medium supple- 
mented with or without 15% FBS for 11 
days. The hatched bars represent abso- 
lute antigenic C 3  levels (ng/ml) in super- 
natants obtained from A549 Dneurnocvte 
vs 290.9 5 47.5 ng C5/m1/24 h). These data  are  further 
substantiated by examination of several  independent ex- 
periments as shown in Figure 3. For example, A549 
pneumocytes cultured in serum-free medium plus LPS 
had an S I  for  antigenic C5 production of SIc5 = 1.16 & 
0.04 ( n  = 8), and  an SI  for functional C5 production of 
SIcsr = 0.98 f 0.01 (n  = 6) during 11 days in culture. 
Additionally, analysis of culture  supernatants from A549 
cells cultured in medium supplemented with FBS and 
LPS demonstrated that LPS had  no effect on either anti- 
genic C5 or functional C5 production, i.e., SIc5 = 0.93 & 
0.02 ( n  = 9) and SIcBl = 0.98 f 0.01 ( n  = 6). respectively. 
Investigation of the percent functional C5 activity de- 
tected in these A549 pneumocyte culture  supernatants 
revealed that LPS had  no  effect on functional C5 activity 
during 11 days in culture. For example, on day 5 in 
culture  when maximum functional C5 activity was  gen- 
erally observed, A549 cells maintained in serum-free 
medium produced 70.0 & 6.9% functional C5 activity ( n  
= 6)  and A549 cells cocultured with LPS produced 75.9 
f 4.6%  functional C5 activity ( n  = 3). A549 pneumocytes 
maintained  in FBS-containing medium,  with  or without 
LPS, also  had  similar  percent  functional  C5  activities on
day 5 (113.1 f 4.4 (n  = 3) vs 108.6 k 14.8 ( n  = 4). 
respectively). 
LPS and protein synthesis by A549 pneurnocytes. 
Our studies  demonstrated that LPS significantly  stimu- 
lated C3  production by type I1 pneumocytes,  but  had no 
effect on C5 production. To further investigate the spec- 
ificity of this response, and to  determine if this response 
was related to effects on protein synthesis, we examined 
the effects of LPS on total protein synthesis by A549 
pneumocytes. This  was accomplished using two meth- 
ods: 1)  analysis of the total  accumulated protein levels in 
serum-free cell culture supernatants using a sensitive 
protein-dye binding assay,  and 2)  analysis of the total 
synthesis of proteins as measured by incorporation of 
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FLgure3. Effect of LPS on C3 and C5 production by A549 pneumo- 
cytes.  The open symbols represent the mean stimulation index (SI) cal- 
culated for culture supernatants obtained from A549 pneumocyte cul- 
tures maintained in medium without 15% FBS (-) plus 100 g / m I  LPS for 
1 1  days. The line graphs represent SI for antigenic C3 (n  = lo),  antigenic 
C5 (n  = 8). and functional C5 (n = 6). The cfosed symbols represent the 
mean SI calculated for culture supernatants obtained from A549 pneu- 
mocyte cultures maintained in  medium with 15% FBS (+] plus 100 pglml 
antigenk C5 (n  = 9). and functional C5 (n = 6). The SEM was  less than 
LPS for 11 days. The line graphs represent S I  for antigenic C3 (n  = 9). 
10% for all data presented. 
a direct measurement of protein  synthesis. Analysis of 
total  accumulated  protein levels in  serum-free cell culture 
supernatants  using a sensitive protein-dye binding 
method demonstrated that A549 cells cultured  in serum 
free medium with  or  without LPS had  identical rates of 
protein synthesis,  10.3 pg protein/ml/24 h. For the radio- 
active  amino acid incorporation  studies, A549 cells were 
cultured with LPS in serum-free conditions for 5 days 
and given a 16-h pulse period with [35S]methionine. The 
results of these  studies  demonstrated that  the SI of radio- 
active amino acid incorporation for LPS-treated A549 
cells was S I R  = 0.83 f 0.02 ( n  = 4). A549 cells cultured 
with LPS in FBS containing  conditions  had a stimulation 
index of SIR = 1.01 f 0.01 ( n  = 3). Inasmuch as alterations 
in the C3 and C5 levels in  these  cultures could be influ- 
enced by C3/C5 catabolism (Le., proteolytic degradation), 
studies to address  the  stability of these  C  proteins were 
undertaken. For these  studies, *251-labeled C3 or C5 was 
added to control and LPS-stimulated cell cultures  main- 
tained  in the  absence  and presence of  FBS. After 6 days 
in  culture,  the  culture  supernatants were analyzed by 
SDS-PAGE and  the radiolabeled C3 and C5 were found 
to  be intact  and not  fragmented,  documenting  the  stabil- 
ity of these C  proteins.  These  observations  suggest that 
LPS stimulation of C3 production by A549 pneumocytes 
may be a reflection of specific  effects on: 1) induction of 
C3 gene  expression; 2) stabilization of C3 mRNA levels; 
or 3) increased C 3  secretion (i.e., posttranslational ef- 
fects),  and not  a  result of generalized effects  on  the cells' 
protein synthetic  capabilities or proteolytic degradation. 
Regardless of the exact  mechanism(s), it is clear that LPS 
selectively enhances production of C3, but not C5 by 
A549 pneumocytes. 
Effect of LPS on C component production by lung 
fibroblasts. To determine if the effects of  LPS on C 
component production by A549 pneumocytes were spe- 
cific to this cell population or generalized effects of LPS 
on all human  lung cells, we evaluated the effects of LPS 
on human  lung fibroblast production of C3  and C5. Con- 
fluent  cultures of WI-38 fibroblasts were maintained for 
11 days in serum-free medium or FBS-containing me- 
PRODUCTION 
dium,  with or without LPS.  Addition of LPS  did not alter 
the morphology of the WI-38 fibroblasts as determined 
by phase contrast microscopy. Analysis of C3  and C5 
production demonstrated that LPS  did not  stimulate or 
suppress C3 or C5 production by  WI-38 fibroblasts, e.g., 
WI-38 cells cultured  in FBS had  a SIc3 = 1.09 f 0.07 (n = 
12),  and a SIc5 = 1.02 f 0.04 ( n  = 12) during 1 1  days in 
culture  (i.e.,  days 1, 3, 5, 7, 9, and 11). Thus, LPS at a 
concentration of 100 pg/ml does not appear to be an  
agent that regulates  C  component production by all hu- 
man  lung cells in vitro. 
DISCUSSION 
Our  understanding of the importance of the C system 
in host defense and inflammation has grown signifi- 
cantly from the original observations over a century ago 
that  serum contained heat labile proteins which were 
bactericidal. Today, the C  system is  seen as a complex 
cascade of biochemical reactions which not only play a 
central role in host  defense and inflammation,  but  have 
been implicated as regulatory molecules in  immune  re- 
sponses, as  well as the coagulation pathway  (25).  Inas- 
much as the activation of the C  system is dependent  on 
a variety of biochemical and enzymatic reactions, the 
functional  expression of the C system is clearly controlled 
by both the absolute amounts, as well as relative concen- 
trations, of the various C components and regulatory 
molecules present  within  the tissue. Previously, control 
of the  tissue levels of individual C  components  was  gen- 
erally believed to be a result of only changes  in vaso- 
permeability. More recently,  questions  have been raised 
about  the xistence and significance of local C  component 
synthesis and secretion  in the regulation of host  defense 
and inflammation within tissues (26). Generally, these 
investigations  into  cellular  synthesis and secretion of C 
components  have been limited to the monocyte/macro- 
phage (27). These studies have demonstrated that the 
monocyte/macrophage has  the capability to synthesize 
many  C  components and regulatory proteins,  including 
C1, C4, C2, C3, C5, factor B, factor D, factor H, factor I, 
properdin, and C1 inhibitor (28-31). Interestingly, the 
monocyte/macrophage has not yet been demonstrated to 
produce the  terminal components of the C system, i.e., 
the  membrane  attack complex /C6. C7, C8,  C9) (32). More 
recently,  studies  have described a variety of factors  or 
agents that can regulate the ability of the monocyte/ 
macrophage to produce C  components  in vitro, e.g., Ag- 
sensitized SRBC, immune complexes, LPS, and IFN-y (1 6, 
29, 33, 34). Thus,  these  studies clearly demonstrate  the 
ability of at least  one population of inflammatory cells to 
synthesize and secrete  numerous C components  in vitro, 
and that this production can be regulated by various 
factors. Based on these  data various  investigators  have 
suggested that in vivo, local production of these C com- 
ponents  within  the  tissue may play an important role in 
controlling host defense, inflammation, and tissue re- 
pair. 
Although these studies have provided important in- 
sights  into  the potential  contribution of recruited cells to 
local concentrations of C components, very little is known 
about  the  contribution of tissue cells to local C levels. TO 
begin to fill this  important  gap  area,  our laboratory has 
recently demonstrated the capability of human type I1 
pneumocytes, i.e., primary  cultures  and a  continuous cell 
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line,  to  synthesize and secrete C3  and C5 in vitro (1 1- 
13). Additionally, these studies also demonstrated the 
ability of human type I1 pneumocytes  (A549) and  human 
lung  fibroblasts (WI-38) to  synthesize and secrete  a  num- 
ber of other  C  components  in  vitro, e.g., Clr, CIS, c4,  C6, 
C7, C8, C9, factor B, and  the regulatory proteins factor 
H. factor I, and Cls inactivator (1 1). Recent studies by 
Strunk  et al. (15) using primary  cultures of human type 
11 pneumocytes have supported our observations on C 
production (i.e., C2, C4, C3, C5, and factor B) by pneu- 
mocytes. Comparison of our  in vitro studies on C produc- 
tion by A549 pneumocytes  with  studies of the monocyte/ 
macrophage indicates: 1) that A549 pneumocytes and 
WI-38 fibroblasts produce 20-  to 50-fold more C3  (anti- 
genic] than isolated human mononuclear cells, and 2) 
A549 pneumocytes and WI-38 fibroblasts produce 10- 
20 fold more C 3  (antigenic) than  the  human monocyte- 
like cell line U937 (14).  These  data clearly indicate that 
on a  per cell basis,  the type I1 pneumocyte and fibroblast 
likely represent a major source of C component produc- 
tion  within  the lung.  These data  assume additional im- 
portance in light of the  fact  that: 1) within  the normal 
lung alveoli, tissue  epithelial cells are  far more numerous 
than alveolar  macrophages, and 2) that  the  number of 
type I1 pneumocytes markedly increases as a result of 
lung injury (35-39). Therefore, in addition to alveolar 
macrophages, it is likely that in vivo type I1 pneumocytes 
and fibroblasts may represent  a  significant  source of C 
components  within the lung. 
Our present  studies  have focused on the capability of 
LPS to  regulate C component production by lung cells. 
Initially our studies demonstrated that A549 pneumo- 
cytes  cultured  in medium supplemented  with FBS pro- 
duced greater levels of C3  and C5  when compared to cells 
cultured  in  serum-free medium. This difference is likely 
a  result of nutrional  effects of the FBS, as well as  the 
effects of hormones, growth factors,  or  cytokines  in  the 
FBS, which may have an  influence on C production by 
the cells. Additionally, our studies demonstrated that 
although LPS had no effect on C3 and C5 production by 
WI-38 fibroblasts, LPS stimulated a two- to threefold 
increase in C 3  production by A549 pneumocytes. Specif- 
ically, the observation that LPS stimulated  a  greater  in- 
crease  in  C3 production by A549 pneumocytes  cultured 
in  serum  free conditions compared to cells in FBS con- 
ditions may be a  result of: 1) lower baseline production 
of C3 by A549 pneumocytes  cultured  in serum  free me- 
dium vs FBS containing  medium,  and/or  2) LPS inacti- 
vation by factor(s)  in FBS or  factors  secreted by A549 
pneumocytes  cultured  in the presence of FBS. The pos- 
sibility that LPS may be inactivated by factors  in FBS is 
supported by studies of Ulevitch and Johnston  (40)  which 
demonstrated that interactions of LPS with serum inhibit 
a number of endotoxic activities of LPS. Interestingly, 
although LPS had  a  stimulatory  effect on C3 production 
by the A549 cell, LPS had no effect on either  antigenic 
or  functional C5 production or total protein synthesis. 
Recently, studies by Strunk  et  al. (1 5) demonstrated that 
LPS stimulated C3 production in  primary  cultures of type 
I1 pneumocytes, but  not  C5  production.  These  data dem- 
onstrate  that  the effects of LPS on C3 production were 
not generalized but  appear specific, in that they occurred 
without a comparable  effect on  total protein synthesis or 
on C5 production by the type I1 pneumocytes. The in- 
crease  in  C3 production induced by LPS in A549 cells 
may be the result of a specific increase in gene  expression 
and/or secretion of C3. Therefore, although C3 gene 
expression may be inducible in human type I1 pneumo- 
cytes by LPS, the C5 gene is  either  not LPS inducible or 
it is a constitutive gene that  is already maximally in- 
duced. In several previous studies, in vitro and in vivo 
regulation of C3 production have been described. For 
example, Strunk  et al. (1  6)  have reported that LPS and 
specifically the lipid A component of LPS, increased C3  
protein synthesis  in  adult  human mononuclear phago- 
cytes, and  enhanced factor B synthesis, yet  did not in- 
crease  synthesis of C2, lysozyme, or effect total protein 
synthesis  in  these cells.  The  mechanism  responsible for 
this  enhanced C3 synthesis in the monocyte was  deter- 
mined to  be largely at  the pretranslational level because 
the concentration of C3-specific mRNA was  increased at 
least fivefold. In other  studies, hydrocortisone has been 
documented as another specific stimulus for C3 produc- 
tion  in a rat hepatoma cell line whereas production of  C2 
and C5 was not effected (41).  These  observations, as well 
as our  own,  support  the concept that C3 production can 
be regulated independently from other  component pro- 
teins. Recently, Katz et al. (6) have demonstrated the 
ability of LPS and IFN-7 to increase C2 and factor B 
synthesis in fibroblasts. Therefore, factors that would 
enhance  the local production of C  components, Le.,  LPS, 
would likely enhance local pulmonary  host  defense. Al- 
ternatively,  factors that would suppress  the local produc- 
tion of C  components and regulatory proteins would likely 
compromise primary  lung  defense  against  infection. 
Thus, our  studies not only demonstrate  the ability of 
LPS to selectively regulate complement production (i.e., 
C3) by A549 pneumocytes,  but that  this regulation may 
be unique  to the type I1 cell, because it does not occur in 
the  lung fibroblast. Additionally, the recent  studies by 
Strunk  et al. (15). which suggest that LPS can regulate 
C3  production,  but  not C5 production in  primary type I1 
pneumocyte cultures  support  the  usefulness of the A549 
pneumocyte cell line as a valid  model for investigating  C 
production and mechanisms of regulation.  Furthermore, 
the A549 cell line has the advantage of being readily 
available, as well as lacking other  contaminating cells 
(e.g., macrophages]  which can complicate data  interpre- 
tation when primary cell cultures  are studied. Clearly, 
further  studies  to  delineate  the capability of lung cells 
such as  the type I1 pneumocyte, alveolar macrophage, 
and  fibroblast o synthesize,  secrete,  and  activate  factors 
of the C system, as well as to identify regulatory mecha- 
nisms, will likely add  to  our  understanding of the molec- 
ular  basis of inflammation and host  defense in the lungs. 
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